Earnings Ahead

DMAC - DiaMedica Therapeutics

4.25 -0.15 -3.41

DiaMedica Therapeutics

DiaMedica Therapeutics

About

Profile


Headquarters


Intraday

High
-
Low
-

52-week

High
-
Low
-

DMAC



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • DiaMedica Therapeutics GAAP EPS of -$0.52 in-line
  • FDA clinical holds pick up amid race for risky, innovative medicines – WSJ
  • DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03
  • DiaMedica stock slides 17% after hours as FDA maintains clinical hold on DM199 trial
  • DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.05
  • Yatsen Holding, CytomX Therapeutics among premarket losers' pack
  • FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
  • DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.07
  • DiaMedica Therapeutics GAAP EPS of -$0.65 beats by $0.08
  • DiaMedica Therapeutics appoints chief medical officer
  • DiaMedica Therapeutics EPS beats by $0.05
  • DiaMedica gets FDA Fast Track status for acute ischemic stroke treatment DM199
  • DiaMedica Therapeutics to undertake $30M private equity offering
  • DiaMedica Therapeutics EPS beats by $0.05
  • DiaMedica Therapeutics adds two industry veterans to its board of directors
  • Intellia and gene editors lead weekly healthcare gainers; CEL-SCI and Citius trail
  • Cerevel Therapeutics, Avinger leads healthcare gainers; DiaMedica Therapeutics, MediWound among major losers
  • Diamedica shows mixed results for kidney disease therapy in mid-stage study
  • DiaMedica gets FDA clearance to initiate phase 2/3 acute ischemic stroke trial
  • DiaMedica Therapeutics reports Q1 results
Date Price Open High Low Vol Change ER
Mar 9 2.640 2.560
2.660
2.530
19.49K 6.88%
Mar 8 2.470 2.431
2.660
2.360
51.36K 0.82%
Mar 7 2.450 2.440
2.560
2.420
19.72K 0%
Mar 4 2.450 2.470
2.550
2.420
41.35K -3.16%
Mar 3 2.530 2.640
2.670
2.500
37.70K -3.44%
 
Mar 2 2.620 2.620
2.645
2.540
15.94K 1.95%
Mar 1 2.570 2.610
2.700
2.570
39.89K -2.28%
Feb 28 2.630 2.600
2.730
2.530
21.84K 0%
Feb 25 2.630 2.780
2.790
2.540
35.75K -5.4%
Feb 24 2.780 2.590
2.810
2.510
48.76K 1.83%
Feb 23 2.730 2.860
2.860
2.680
28.48K -2.85%
Feb 22 2.810 2.890
2.900
2.760
27.09K -0.35%
Feb 18 2.820 3.000
3.019
2.750
109.98K -6.93%
Feb 17 3.030 3.190
3.200
2.980
135.89K -2.57%
Feb 16 3.110 3.100
3.225
3.040
63.55K 0.32%
Feb 15 3.100 3.080
3.100
2.940
18.76K 3.33%
Feb 14 3.000 2.920
3.060
2.900
50.49K 1.69%
Feb 11 2.950 3.040
3.090
2.900
52.31K -3.59%
Feb 10 3.060 2.970
3.100
2.910
55.21K 0.33%